A new Clinical Trial is now open at LINEAR Research Institute:


This study is for patients with Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) and Non-Hodgkin lymphoma (NHL) who have failed or are intolerant to standard of care treatment.

The study includes two parts:
Phase 1 is a dose escalation, where the maximum tolerated dose of LOXO-305 will be evaluated
Phase 2 is a dose expansion, where patients will receive the established recommended dose of LOXO-305

For further information and contact details, please see our Open to Recruitment page: